The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association
Abstract
Use of ambulatory blood pressure monitoring in children and adolescents has markedly increased since publication of the last American Heart Association scientific statement on pediatric ambulatory blood pressure monitoring in 2014. In addition, there has also been significant expansion of the evidence base for use of ambulatory blood pressure monitoring in the pediatric population, including new data linking ambulatory blood pressure levels with the development of blood pressure–related target organ damage. Last, additional data have recently been published that enable simplification of the classification of pediatric ambulatory monitoring studies. This scientific statement presents a succinct review of this new evidence, guidance on optimal application of ambulatory blood pressure monitoring in the clinical setting, and an updated classification scheme for the interpretation of ambulatory blood pressure monitoring in children and adolescents. We also highlight areas of uncertainty where additional research is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies of”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In general, these studies found that GLP-1–based therapies would not be cost-effective compared with usual care, especially when used as first-line therapy.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SGLT2i appear to primarily reduce incident and worsening HF.17,37–44”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Based on the results across these trials, it is likely that finerenone confers both cardiovascular and kidney benefits in those with albuminuric DKD and HFmrEF/HFpEF, though a more dedicated study of this population is needed.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“in FINEARTS-HF alone, finerenone did not result in a reduction in the primary kidney endpoint.44”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In end-stage kidney disease on dialysis, 2 high-quality observational studies using data from the US Renal Data System found that apixaban was associated with lower major bleeding and similar mortality compared to warfarin.43,44”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Exercise interventions improve quality of life and several cardiometabolic parameters, even in those with advanced liver disease.44,45”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Decreases in eGFR up to 30% after initiation of a RASi or MRA are expected and acceptable.44”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
Self-citationMeasurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association
Muntner, P., Shimbo, D., Carey, R. M., Charleston, J. B., Gaillard, T., Misra, S., Myers, M. G., Ogedegbe, G., Schwartz, J. E., Townsend, R. R., et al. (2019) · Hypertension · doi:10.1161/hyp.0000000000000087 · Cited by 1,512
Self-citationLurbe, E., Agabiti-Rosei, E., Cruickshank, J. K., Dominiczak, A., Erdine, S., Hirth, A., Invitti, C., Litwin, M., Mancia, G., Pall, D., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001039 · Cited by 1,379
Aortic Stiffness, Blood Pressure Progression, and Incident Hypertension
Kaess, B. M., Rong, J., Larson, M. G., Hamburg, N. M., Vita, J. A., Levy, D. A., Benjamin, E. J., Vasan, R. S., & Mitchell, G. F. (2012) · JAMA · doi:10.1001/2012.jama.10503 · Cited by 1,086
Strict Blood-Pressure Control and Progression of Renal Failure in Children
The ESCAPE Trial Group (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902066 · Cited by 954
Wühl, E., Witte, K. K., Soergel, M., Mehls, O., & Schaefer, F. S. (2002) · Journal of Hypertension · doi:10.1097/00004872-200210000-00019 · Cited by 816
Brien, E. O., Petrie, J. C., Littler, W. A., de Swiet, M., Padfield, P. L., O??Malley, K., Jamieson, M., Altman, D. G., Bland, M., & Atkins, N. (1990) · Journal of Hypertension · doi:10.1097/00004872-199007000-00004 · Cited by 764
Update: Ambulatory Blood Pressure Monitoring in Children and Adolescents
Flynn, J. T., Daniels, S. R., Hayman, L. L., Maahs, D. M., McCrindle, B. W., Mitsnefes, M. M., Zachariah, J. P. V., & Urbina, E. M. (2014) · Hypertension · doi:10.1161/hyp.0000000000000007 · Cited by 608
Self-citation
Cited by
Sorted by citations
Falkner, B. E., Gidding, S. S., Baker-Smith, C. M., Brady, T. M., Flynn, J. T., Malle, L. M., South, A. M., Tran, A. H., & Urbina, E. M. (2023) · Hypertension · doi:10.1161/hyp.0000000000000228 · Cited by 168
Self-citationDevuyst, O., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., Gall, É. C.-L., Drenth, J. P. H., Gansevoort, R. T., Harris, P. C., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.07.009 · Cited by 149
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 91
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citation
Metadata
- Authors
- Flynn, J. T., Urbina, E. M., Brady, T. M., Baker-Smith, C., Daniels, S. R., Hayman, L. L., Mitsnefes, M., Tran, A., Zachariah, J. P., & on behalf of the Atherosclerosis, H.
- ORCID
- Venue
- Hypertension
- Published
- 2022-07
- Volume
- 79
- Issue
- 7
- Pages
- e114-e124
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- PMC
- PMC12168719
- OpenAlex
- W4281298204
- Cited by
- 202
- References
- 57
- Citations by year
- 2026: 61 · 2025: 50 · 2024: 42 · 2023: 38 · 2022: 11
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL148217)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Physical Sciences › Engineering › Biomedical Engineering › Non-Invasive Vital Sign Monitoring
- Keywords
- ambulatory blood pressure monitoring, pediatric hypertension, children and adolescents, target organ damage, blood pressure classification, hypertension diagnosis
- MeSH terms
- Adolescent, American Heart Association, Blood Pressure, Child, Humans, Hypertension, United States, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
